{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-005435","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.340872+00:00","generated_at":"2026-05-28T02:05:26.447313+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics outlines 2025 milestones: paltusotine PDUFA Sept 25, atumelnant Ph3 start H1 2025","bullets":["Paltusotine NDA under FDA review; PDUFA target action date set for September 25, 2025.","Atumelnant Phase 3 initiation for adult CAH patients expected in H1 2025; pediatric CAH and Cushing's disease later-stage trials planned in 2025.","Four development candidates advancing toward IND-enabling studies for NETs, hyperparathyroidism, Graves' disease, thyroid eye disease, and ADPKD.","CEO Scott Struthers presenting at 43rd J.P. Morgan Healthcare Conference on January 14, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-005435","json":"https://secwatch.observer/filing/0000950170-25-005435.json","markdown":"https://secwatch.observer/filing/0000950170-25-005435.md","text":"https://secwatch.observer/filing/0000950170-25-005435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025005435/0000950170-25-005435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025005435/crnx-20250114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:05:26.447313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}